MedTrace Logo

Chemotherapy / Radiotherapy in Uterine Cervical Neoplasms

NCT03238261 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 147

Last updated 2017-08-11

No results posted yet for this study

Summary

Compare the use of radiotherapy and concomitant chemotherapy, with the single use of radiotherapy in the treatment of patients with stage IIIB uterine cancer, having as an outcome the three year survival rate, the disease free survival rate, the locoregional control of the disease and the security of the treatments provided.

Specific objectives

1. Describe and compare the demographic and clinical characteristics of both groups.
2. Compare the three year survival rate in both groups.
3. Compare the response to treatment in terms of locoregional control of the disease.
4. Compare the appearance of severe and non severe adverse events directly related to the treatment in both intervention groups.

Conditions

  • Uterine Cervical Neoplasms

Interventions

RADIATION

Chemotherapy and concomitant radiotherapy

Radiotherapy (teletherapy + high or low rate brachytherapy)

Sponsors & Collaborators

  • Instituto Nacional de Cancerologia, Columbia

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-01
Primary Completion
2012-02-01
Completion
2016-05-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03238261 on ClinicalTrials.gov